ahlam1399
09-07-2015, 06:52 PM
Companies struggle to get new medicines adopted across Europe
LONDON (Reuters) - Pharmaceutical companies, currently enjoying a bumper wave of new drug launches, are struggling to get recently introduced products adopted in key European markets as governments bear down on costs.
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2.img (http://da.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/ach.img (http://adchoice.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/ach.htm)http://pi.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2t.imghttp://pi2.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/49a3ce59/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zU5PWBB7xLA:1h24eNdTud4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zU5PWBB7xLA:1h24eNdTud4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/zU5PWBB7xLA
LONDON (Reuters) - Pharmaceutical companies, currently enjoying a bumper wave of new drug launches, are struggling to get recently introduced products adopted in key European markets as governments bear down on costs.
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2.img (http://da.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/ach.img (http://adchoice.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/ach.htm)http://pi.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2t.imghttp://pi2.feedsportal.com/r/238385398522/u/49/f/654207/c/35217/s/49a3ce59/sc/28/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/49a3ce59/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zU5PWBB7xLA:1h24eNdTud4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zU5PWBB7xLA:1h24eNdTud4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=zU5PWBB7xLA:1h24eNdTud4:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/zU5PWBB7xLA